We are live on ! Find out more
AMRX icon

Amneal Pharmaceuticals

21.52 USD
+0.08
0.37%
At close Updated Oct 28, 9:46 AM EDT
1 day
0.37%
5 days
5.91%
1 month
4.98%
3 months
14.71%
6 months
68.92%
Year to date
69.98%
1 year
109.14%
5 years
294.86%
10 years
43.37%
 

About: Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Employees: 8,500

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 47.8%
Neutral 47.8%
Negative 4.3%
Positive
Zacks Investment Research
22 hours ago
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Positive
Zacks Investment Research
23 hours ago
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Neutral
Zacks Investment Research
23 hours ago
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
Positive
Zacks Investment Research
1 day ago
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Neutral
GlobeNewsWire
20 days ago
Amneal to Report Third Quarter 2026 Results on November 3, 2026
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
Amneal to Report Third Quarter 2026 Results on November 3, 2026
Neutral
GlobeNewsWire
1 month ago
Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Positive
Zacks Investment Research
1 month ago
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Neutral
Zacks Investment Research
2 months ago
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
Negative
Zacks Investment Research
2 months ago
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
Neutral
Business Wire
2 months ago
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
Price charts implemented using Lightweight Charts™